Therapeutic Response

HER2-negative and PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.

Statements

Source and description
Femara (letrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.